Company intelligence
Kurin Inc.
Reshaping Blood Culture Collection Standard of Care
About Kurin Inc.
Kurin® is a privately held, certified minority owned business dedicated to engineering better healthcare through innovative, cost-effective, clinician-approved technologies. Building on the successful invention, clinical adoption, and corporate acquisition of Curos™ disinfecting port protectors, Kurin is focusing its depth of experience in medical device engineering, marketing, sales and service, to tackle the persistent and costly fallout of false positive blood cultures. With agile development capabilities and intense customer focus, we have seen the Kurin Lock® with Flash Technology quickly gain caregiver acceptance, sideline skin contaminants during blood culture collection, and become the blood culture collection standard of care in hospitals. Curos™ is a registered trademark of 3M Corporation.
Verified activity
Signals from Kurin Inc.
3 published signals
Research & Knowledge
Kurin Inc. published a study published in the Journal of Clinical Microbiology by a Johns Hopkins-led multicenter study involving 52 U.S. hospitals and 362,000 cultures, finding that 65% of hospitals use CAP criteria, 17% use CLSI, and 17% use the broader NHSN skin-commensal list.
Reported by Daniel Chadwell
Presence & Recognition
Kurin Inc. celebrated the Clinical Nurse Specialists this week with the theme Amplify: Making the Invisible Indispensable.
Reported by Kurin Inc.
Research & Knowledge
Kurin Inc. published a new 2026 CLIA Request for Information (RFI) in the Federal Register open for public comment through September 14, 2026.
Reported by Daniel Chadwell